Stage 4 Colon Cancer Treatment
Overcoming Colon Cancer Statistics with Treatments Designed to Attack Cancer at its Cause
Understanding new and innovative approaches to advanced colon cancer can help patients adopt critical options to treatment that they are currently missing. In our two decades of working with late-stage colon cancer patients we have found that a personalized approach using the best genomic and immunotherapy targets can make a big difference. The reason so many patients struggle with devasting chemotherapy and radiation treatment failures, and the often side-effects that destroy their overall health, is because they were lacking in high-level personalization.
ICCA is a center of excellence for personalized oncology and stacks the odds in our patients' favor by integrating personalized genetically-driven protocols utilizing the best in research-based natural medicine and world-class conventional therapies. If you are looking for advanced care from invested and receptive doctors who take a personalized and integrative approach, beyond what can be found at other clinics, to treating your colon cancer, Integrative Cancer Centers of America may be exactly what you are looking for and here is why.
Late-stage metastasized cancer is very difficult to treat, and colon cancer is no exception. Stage four colon cancer has a 10% 5-year relative survival rate with standard chemotherapy . Standard chemotherapy and conventional treatment are largely ineffective against late-stage colon cancer and, in our clinical opinion, most standard oncology is focused on management of the disease as opposed to pursuing substantial results. It's the, "let the patient die with dignity mantra" the plagues almost every cancer center and hospital in this country instead of fighting to help the patient live and overcome.
At ICCA our goals are to pursue lasting progress in the fight against colon cancer, regardless of the cancer's staging. Many of the patients who come to see our physicians have already exhausted their options in standard oncology and clinical trials and are now looking for more personalized treatment solutions. We've treated late-stage cancer patients who have been recommended hospice care, all but given up on by the conventional system, and have seen success. Look no further than Sandy.
Sandy is one of Integrative Cancer Centers of America's earliest patients. She was diagnosed with late-stage metastatic colon cancer in 2001. She was given a 20% survival rate and was told there was a 90% chance that her colon cancer would be back within a year if she managed to enter remission. We are elated to say that it has been more than 17 years since Sandy came to Integrative Cancer Centers of America looking for a better way to fight against her colon cancer, and with our help, she is healthy and cancer free to this day. We were able to accomplish remarkable life-saving results with very limited technology at the time.
The technology we provide at ICCA today is light years ahead of what we could offer Sandy and that speaks volumes about the innovations we have brought to the forefront to help improve our patient outcomes. At Integrative Cancer Centers of America, we see our patients as individuals instead of numbers and statistics or protocols. We know that to achieve true progress, the creation of genetically targeted immunotherapy and personalized treatment protocols that are unique to the patient's colon cancer and physical status is key.
Colon cancer is one of the most common cancers in the world and Integrative Cancer Centers of America is very familiar treating patients with all stages of colon cancer. Only 5% of colon cancer is a result of inherited genetic mutations .That means 95% of colon cancer cases develop as a result of altered gene expression caused by diet and environmental factors like infections, heavy metal exposure, and chemical toxins. This modification of gene expression is called epigenetics and is manifested within the patient's miRNA which is responsible for the informational coding for the up-regulation of tumor oncogenes and the down-regulation of tumor suppressor genes.
The standard approach to treating colon cancer involves invasive surgery and debilitating chemotherapy using the maximum therapeutic dose (the highest dose the body can possibly withstand) to try and eradicate the tumor. This has a very detrimental effect on the patient's body. Furthermore, standardized chemotherapy uses data from huge clinical trials to prescribe generic, "one-size-fits-all," treatments based on staging and cancer type. In our clinical opinion, this is an outdated and ineffective method for treating late-stage cancer that expresses unique mutations in every patient.
ICCA offers a more efficient and less destructive system for treating colon cancer. We specialize in late-stage metastasized cancer that have become aggressive, resistant to treatment, and recurrent. We utilize an integrative approach that combines the most effective research-based integrative solutions with proven conventional treatments from around the world, specifically targeting the patient's colon cancer using genetic information like biomarkers, molecular profiles, and oncogenes. With this information, we can precisely approach colon cancer by developing proprietary chemotherapy and immunotherapy options in our own custom pharmacy that are personalized to our patient's targets, providing them a greater chance to respond. This makes ICCA's approach more personalized and unique to all other oncology systems.
Targeted Chemotherapy: Biomarkers
The standardized approach to cancer care involves using chemotherapy drugs based on cancer type and staging. This information comes from huge clinical trials that test chemotherapy drugs on thousands of patients to see which drugs may have a positive response. This approach labels each patient as a statistic and a survival rate is determined based on the clinical trial data while ignoring the patient's epigenetic profile and cancer markers.
ICCA takes a more advanced and personalized approach to colon cancer care. We see each patient as an individual and customize care to give each patient the best chance to regain their quality of life. We know that each condition is unique; everything from the distinct causes and contributing factors of that cancer, to its specific genetic makeup are individual to the patient. ICCA uses state-of-the-art testing and actual face-to-face time with our doctors to gather all the information surrounding the colon cancer and compile a true medical blueprint. With this blueprint, we can customize treatment plans to fit the patient's personal needs while using biomarker and genetic information on the patient's specific cancer to precision-target with our proprietary chemotherapy treatment options and immunotherapy programs.
Biomarkers are the gate keepers of cells and they signal what is okay to let into the cell and what to keep out. Through a simple blood draw, we can access your circulating tumor cells and gather the most recent information on your cancer's genetic makeup. There are many benefits to looking at your circulating tumor cells as opposed to taking the standardized approach which involves tumor biopsy. For one, circulating tumor cells are much easier to access than tumor biopsy; circulating cancer cells can be accessed through a simple blood draw and does not need invasive surgery. Second, circulating tumor cells represent the most recent mutations of your cancer and therefore give us the best information about your colon cancer's trajectory. Cancer cells are constantly mutating and the more time that passes between biopsy and treatment the more the cancer changes. By looking at the circulating tumor cells, we get the most recent data on your colon cancer mutations which enables our treatment to be dynamic and constantly evolving to stay ahead of the mutations.
Genetically Targeted Fractionated Chemotherapy: A More Advanced Chemotherapy Treatment Option
At ICCA, we believe that Genetically Targeted Fractionated Chemotherapy, or GTFC, is the future of oncology. "Genetically targeted" refers to our ability to identify and track the genetic information about a patient's cancer including biomarkers, molecular profile, and chemo-susceptibility. We use different chemotherapy options based on genetic testing to determine which ones are most effective against that particular cancer . With this targeted information we now know which chemotherapies and natural agents the cancer is most likely to respond to. Because we know which agents should cause a response in the cancer, we are able to utilize metronomic dosing, often delivering 1/10 of the chemotherapy you would receive at a traditional clinic. This micro dose of chemotherapy allows us to use multiple targeted agents at once with far less side-effects for our patients.
Oftentimes the patients we see complain that the chemotherapy treatments they received at their previous clinics were worse than the cancer itself. With GTFC our patients are not bed-ridden with horrible side-effects, they are out living their lives and doing the things they love with the people they care about. They even enjoy doing extreme activities like hiking, something a person on a traditional chemotherapy regimen could never do. This is all possible when you have the proper targets and you aren't deploying a barbaric and antiquated regimen of chemotherapy that in our clinical opinion is causing more harm than good when not properly targeted.
This is in stark contrast to the standardized method that relies on generic NCCN guidelines to prescribe chemotherapy based on cancer type and staging. By genetically targeting your colon cancer we can deliver the medication to the cancerous cells more efficiently. Standard chemotherapy can only get about 4-5% absorption of the medication into the cells but at ICCA our goal is to target cancerous cells with 100% absorption of the chemo medication. With increased absorption we do not have to use the large doses needed in standard oncology, we can instead use fractionated doses of chemotherapy .
By using fractionated doses, we can deliver multiple chemotherapy agents at once, hitting more biomarkers and increasing your chances of seeing real progress in your recovery . Also, by using fractionated doses and genetic biomarkers to precision target our chemotherapy we can increase the frequency of treatment while reducing the major side-effects . GTFC has been developed by ICCA over its nearly 20 years of treating late-stage and complex cancer and we believe it stacks the odds in the favor of our colon cancer patients.
Precision Targeted, Minimally Invasive Chemotherapy Options
Utilizing decade of experience in treating refractory to care cancers like late-stage colon cancer,ICCA has developed an exciting new treatment known as CIPI ™, or Chemo Immunotherapy Percutaneous Injections. CIPI ™ utilizes advanced world-class testing and precision genetic targets to provide customized, targeted, and minimally invasive treatment options for patients suffering from colorectal cancer. CIPI ™ was developed by ICCA Medical Center as a unique form of tumor chemoembolization designed to treat inoperable tumors that are fibrous and difficult to penetrate through traditional intravenous chemotherapy methods. CIPI ™ has the potential to revolutionize the treatment of late-stage colorectal cancers by targeting large tumor sites of cancer metastasis.
With CIPI ™, genetically personalized micro-dosed medications are direct injected into the tumor. This supports increased medication delivery and maximized bioavailability, while potentially reducing the side-effects normally associated with aggressive chemotherapy treatments. Chemo Immunotherapy Percutaneous Injections are proving to be a highly sought-after option for patients suffering with advanced or hard to treat colon cancer prognoses where IV administration is not optimal. CIPI ™ is a revolutionary technology that we believe helps our colon cancer patients return to their quality of life.
Immunotherapy and Colon Cancer
Chemotherapy is not the only approach to late-stage colon cancer that we take at ICCA. Immunotherapy plays a major part of our treatment protocol. Immunotherapy has become more and more integral to treating colon cancer as the development of smart drugs has become more advanced. Immunotherapy utilizes genetic information to assist the immune system in finding and killing cancerous cells . The body is naturally very adapted at killing cancerous cells and normally will kill thousands of cancerous and precancerous cells daily . However, mainstream treatments like chemotherapy, radiation, and surgery negatively affect the immune system and many patients come to us with extremely depleted immune systems. This is important because a depleted immune system allows the cancer to continue its spread at an even faster rate since the immune system can no longer target and slow the rate of expansion. Immunity plays a big role in late-stage colon cancer, but it is ultimately dismissed by conventional oncology. Fortunately, ICCA has developed advanced immunotherapy options to help our patients overcome these pitfalls and potentially achieve better outcomes and a return of quality of life.
Some clinics may claim to offer immunotherapy but if the treatment isn't targeted to the patient, poor results can be expected. This is why ICCA has put its resources to work and developed a truly targeted immunotherapy treatment option call Immune Modulation Therapy (IMX). Through world-class testing IMX is able to combine the latest in research-based immunotherapy options from around the world to rebuild the immune system to recognize and destroy cancer. This advanced immunotherapy option is achieved by examining the genetic information of the circulating tumor cells in the body and then relaying this information to natural killer and dendritic cells while combining oncolytic viruses and checkpoint inhibitors to train the immune system to locate and kill the cancer cells. This powerful treatment option works in conjunction with GTFC to provide results that are unmatched in the current oncology realm. Immunotherapy is an important, yet often missed, piece to colon cancer and ICCA is proud to be leading the nation in innovation when it comes to advanced immunotherapy options. Our dedication to advancing the options for patients is what sets ICCA apart and lets our patients know they have found the right place for their care.
(IMX Therapy has not been reviewed or approved by the FDA and is currently only available at our ICCA Mexico facility.)
At ICCA we recognize the power of the immune system to fight cancer; we will look to correctly re-establish a patient's immune system to optimal health and combine that with cutting-edge smart drugs to genetically target and mark cancerous cells for destruction. ICCA strives to provide the most modern and successful immunotherapies from around the world and combine them with our knowledge and experience to give our patients the best immunotherapy options available in the nation.
Since our conception nearly 20 years ago, it has been Integrative Cancer Centers of America's mission to provide the best possible care for our patients, and we have worked tirelessly while continuing to be dedicated to developing technology and therapies to achieve that goal. We are not stunted by the red tape conventional medicine must conform to. We provide options for our patients through multifaceted integrated treatment protocols that utilize many different methods for treating colon cancer from all angles. If you or a loved one is interested in a more advanced approach to treating colon cancer, please contact our Patient Care Coordinators at (888) 526-6398 and learn more about how Integrative Cancer Centers of America can assist you. May God bless you on your journey to healing.
 Haggar, F.A. and R.P. Boushey, Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clinics in colon and rectal surgery, 2009. 22(4): p. 191-197.
 Labianca, R., et al., Colon cancer. Critical Reviews in Oncology/Hematology, 2010. 74(2): p. 106-133.
 Smith, A.J., J. Oertle, and D. Prato, Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy, 2015. Vol.06No.02: p. 17.
 Smith, A.J., J. Oertle, and D. Prato, Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy, 2015. Vol.06No.02: p. 17.